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Abstract
Injury to the glomerular podocyte is a key mechanism in human glomerular disease and podocyte repair is an important
therapeutic target. In Fabry disease, podocyte injury is caused by the intracellular accumulation of globotriaosylceramide. This
study identifies in the human podocyte three endocytic receptors, mannose 6-phosphate/insulin-like growth II receptor,
megalin, and sortilin and demonstrates their drug delivery capabilities for enzyme replacement therapy. Sortilin, a novel a-
galactosidase A binding protein, reveals a predominant intracellular expression but also surface expression in the podocyte.
The present study provides the rationale for the renal effect of treatment with a-galactosidase A and identifies potential
pathways for future non-carbohydrate based drug delivery to the kidney podocyte and other potential affected organs.
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Introduction
Fabry disease is an X-linked lysosomal disorder that results from
mutations of the gene (GLA)t h a te n c o d e sa-galactosidase A (a-Gal A)
[1,2,3]. The enzymatic defect leads to progressive lysosomal
accumulation of globotriaosylceramide (GL-3) and related glyco-
sphingolipids in the kidney and other tissues [3]. Glycosphingolipid
accumulates over time leading to kidney failure, cerebrovascular
manifestations, and heartfailure, and eventually premature death [4].
Nephropathy is a dominant feature in Fabry disease and
impairment of renal function occurs due to progressive accumulation
of GL-3 in a variety of renal cells [3,5,6,7,8]. End-stage renal failure
usually occurs in the third to fifth decade of life, when the lysosomal
GL-3 accumulation becomes irreversible [7,9] and patients are in
need of dialysis or renal transplantation [9,10]. The podocytes are the
renal cells with the most abundant glycosphingolipid deposits
[3,8,11,12,13] and this accumulation appears to be central for the
development of nephropathy in Fabry disease [14,15].
Lysosomal storage diseases in general [16], including Fabry
disease, can now be treated with enzyme replacement therapy
(ERT) [12,17,18,19,20,21,22,23,24,25]. ERT reduces GL-3 de-
posits in podocytes [12,22,26] and can stabilize kidney function in
patients with Fabry nephropathy [27]. Furthermore, for ERT to
be maximally effective, it must be initiated early, before
irreversible renal damage occurs [28,29,30].
Therapeutic effectiveness of a-Gal A is dependent on endocy-
tosis by recognition of mannose 6-phosphate (M6P) residues on the
enzyme by the widely distributed M6P/insulin-like growth II
(IGF-II) receptor [31,32,33]. We previously showed that megalin,
a multiligand receptor, binds a-Gal A and takes up a-Gal A in
proximal tubule cells by receptor-mediated endocytosis [34].
However, the mechanism for the uptake in mouse podocytes in the
same study was not investigated.
We have identified M6PR, but also megalin and sortilin as a-Gal
A binding proteins important for a-Gal A accumulation in human
podocytes by use of different biochemical and morphological
approaches, including affinity chromatography, surface plasmon
resonance analysis, laser microdissection, and immunocytochemis-
try to analyze human podocytes in culture and renal tissue from
Fabry patients. On the basis of these data, we suggest a new and
complex mechanismofa-GalA cellularinternalization inpodocytes
involving the sorting and endocytic receptors M6PR and sortilin
and the high molecular weight endocytic receptor megalin.
Results
Podocytes take up recombinant a-Gal A
We have previously shown that endogenous a-Gal A is not
detectable in normal human podocytes [34]. However in a-Gal A
knockout mice, the enzyme was found in lysosomes of mouse
podocytes 2 h after intravenous injection of recombinant a-Gal A
[34]. To study if this was also the case in humans, we investigated
a renal biopsy from a male Fabry patient infused with a-Gal A.
Two hours after infusion of recombinant a-Gal A, the enzyme was
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biopsy from a male Fabry patient who was not infused with
recombinant a-Gal A demonstrated no detectable a-Gal A in the
podocytes (Figure 1B). Furthermore, the treated male Fabry
patient showed no detectable endogenous a-Gal A in the collecting
ducts (compare Figure 1C to Figure 1D from normal human
kidney with normal expression).
To study in detail the podocyte uptake of a-Gal A, we used
an already established human podocyte cell culture model [35].
Recombinant a-Gal A is also taken up by these condi-
tionally immortalized podocytes showing time-dependent uptake
(Figure 1E). The endocytosed enzyme was localized to the
lysosomes as confirmed by colocalization of LysoTracker-Red
with Alexa-Fluor-488 conjugated a-Gal A (Figure 1F).
Isolation and identification of M6PR, megalin, and sortilin
as a-Gal A-interacting proteins in podocytes
The receptor-mediated uptake of lysosomal hydrolases in
podocytes has so far not been investigated. To identify receptors
involved in the uptake of a-Gal A in podocytes, we employed an
affinity-chromatography approach. A detergent-soluble extract of
cultured podocytes was passed over recombinant a-Gal A affinity
resin, and, following extensive washing, the resin bound proteins
were eluted using pH 3 Glycine buffer. Fractions were collected
and analyzed by SDS-PAGE and silver staining (Figure 2A). A
sample of the same extract was also passed over a control resin to
monitor nonspecific background binding of proteins to the resin.
Comparison of the eluates from the two columns revealed that
three protein bands with apparent masses of 600, 250 and
100 kDa were present in the fractions eluted from the a-Gal A
resin but not the control resin (Figure 2A). To determine the
identity of the proteins, the eluted fractions from the a-Gal A resin
with the highest protein content were run on SDS-PAGE gel
followed by immunoblotting. The proteins were identified as
megalin, M6PR, and sortilin using the corresponding antibodies
(Figure 2B).
125I-labeled a-Gal A uptake in human podocytes
The endocytic activity of megalin, M6PR, and sortilin expressed
by cultured human podocytes was investigated by their ability to
mediate uptake of
125I-labeled a-Gal A (both cell association and
degradation) (Figure 3). M6P, a ligand for M6PR, inhibited the a-
Gal A uptake by approximately 26% after 12 h (P,0.001). RAP, a
ligand for both megalin and sortilin, inhibited 19% (P,0.001), and
Figure 1. Uptake of recombinant a-Gal A by human podocytes. (A) Peroxidase immunohistochemistry for a-Gal A in a biopsy from a male
Fabry patient using anti-human a-Gal A antibody. The patient was intravenously infused with a-Gal A 2 h before the biopsy was taken. Labeling of a
human glomerulus (G) showing a-Gal A localization in the podocytes (indicated with green arrowheads) and GL-3 inclusions seen as vacuoles
(indicated with red arrowheads). Staining is also seen in parietal epithelial cells (indicated with yellow arrows). Scale bar, 25 mm. A high-power view of
a portion of the glomerulus (top-right) demonstrates the localization of infused recombinant a-Gal in the podocyte. (B) For comparison, no a-Gal A
labeling is seen in the podocytes in a biopsy from an untreated male Fabry patient. (C) The treated male Fabry patient shows no detectable labeling
of endogenous a-Gal A in the collecting ducts (CD). Red arrowheads indicate heavy GL-3 inclusions. Scale bar, 25 mm. (D) A normal individual shows
labeling of endogenous a-Gal A (green arrowheads) in both thick ascending limbs of Henle (TAL) and in CD. Scale bar, 25 mm. (E) Immunofluorescent
demonstration of Alexa-Fluor 488-labeled a-Gal A uptake in human podocytes as a function of time at 37uC. At the indicated times, the cells were
fixed and analyzed by confocal microscopy. Scale bar, 10 mm. (F) For colocalization of a-Gal A (green) and lysosomes (red) a merged image is shown.
The yellow color illustrates colocalization. Scale bar, 5 mm.
doi:10.1371/journal.pone.0025065.g001
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the binding/uptake of sortilin ligands [36], inhibited 7% after 12 h
(not significant). Finally, the inhibition by all three ligands
combined was tested, and the uptake of
125I-a-Gal A was inhibited
39% after 12 h (P,0.001).
Sortilin, a new receptor for a-Gal A
Surface plasmon resonance (SPR) analysis for megalin binding
to a-Gal A was shown previously [34] with a Kd of 600 nM.
Biacore analysis of a-Gal A binding to M6PR has already been
shown in previous experiments [37]. We then focused on sortilin,
SPR analysis showed binding of a-Gal A to purified and
immobilized sortilin (Figure 4A). Using the BIAevaluation
program, Kd was estimated to 400 nM. We next examined if
neurotensin (NT), a neuropeptide with high affinity for sortilin
[38], inhibited the binding of a-Gal A to sortilin. At 20 mM, NT
markedly inhibited the binding of a-Gal A to sortilin (Figure 4A)
indicating that NT and a-Gal A bind to sortilin at the same
binding site as the sortilin propeptide. Other members of the
Vps10p (vacuolar protein sorting 10 protein)-domain family [39],
sorLA and sorCS3, did not show significant binding to a-Gal A
(data not shown), and neither did the low density lipoprotein
related protein (LRP). These results further substantiated that
sortilin specifically binds a-Gal A.
Thus we had clear evidence that a-Gal A bound sortilin in order
to demonstrate the ability of sortilin to take up a-Gal A. We
developed a system in which sortilin is expressed in absence of
megalin. We therefore used HEK293 cells stably transfected with
sortilin to demonstrate a-Gal A binding to sortilin and uptake
(Figure 4B). The transfectants expressed full-length sortilin in
contrast to the wild-type cells. When cells were incubated in the
presence of 5 mM M6P uptake by the M6PRs were totally
inhibited in HEK293 wild-type but uptake was still present in the
sortilin transfected HEK293 cells (Figure 4B). Next, we inhibited
with NT and M6P, as shown in Figure 4B. NT at 20 mM
essentially eliminated the binding and uptake of a-Gal A
demonstrating the ability of sortilin to take up a-Gal A.
Cultured human podocytes express megalin, sortilin and
M6PR
We next examined the surface expression of megalin, M6PR,
and sortilin in cultured human podocytes by immunofluorescent
studies under non-permeabilized conditions. It appears that
megalin was predominantly expressed on the cell-surface, whereas
M6PR and sortilin were mainly expressed intracellularly with
some cell-surface expression (Figure 5). The expression of megalin,
M6PR, and sortilin was also studied in permeabilized cells, where
all three receptors demonstrated intracellular labeling (Figure 5).
The phenotype of podocytes was characterized by using podocyte-
specific antibodies to podocin and nephrin under permeabilized
conditions (Figure 5). Controls incubated with serum or IgG
fractions revealed no significant labeling.
Expression of megalin, sortilin, and M6PR in human
glomerular podocytes
To study the expression of megalin, sortilin, and M6PR, we
isolated human glomeruli by laser capture microdissection and
evaluated if the receptors’ mRNAs could be identified by RT-
PCR. In order to avoid contamination with especially proximal
tubule cells only the largest cross sections of the glomeruli from the
10 mm thick cryosections were chosen in order to be close to the
equator, and furthermore the dissection was performed with safe
distance to the glomerular parietal epithelium. To confirm, that
the isolated glomeruli are not contaminated with proximal tubule,
we demonstrate that the proximal tubule marker aminopeptidase
N (APN) [40] is not present in the laser dissected glomeruli
(Figure 6A). The expression of mRNA for megalin, M6PR,
sortilin, podocin and nephrin is shown in the isolated human
Figure 2. Megalin, M6PR and sortilin bind specifically to recombinant a-Gal A in podocytes. (A) Affinity chromatography: the arrowheads
indicate the migration of the different a-Gal A binding proteins. (B) Western blot analysis demonstrated that the three bands were megalin, M6PR,
and sortilin as indicated with arrows. Lysate from human podocyte culture was used as a positive control.
doi:10.1371/journal.pone.0025065.g002
Receptor-Mediated Endocytosis in Podocytes
PLoS ONE | www.plosone.org 3 September 2011 | Volume 6 | Issue 9 | e25065glomeruli and human kidney cortex in Figure 6A. No expression
was observed in the negative controls.
To further confirm that the receptors were indeed expressed in
the human glomerular podocytes, we performed immunohisto-
chemistry studies on human kidney sections. We used three well
characterized polyclonal antibodies to megalin, sortilin, and
M6PR described in the literature. Immunoperoxidase staining
using the three antibodies showed the presence of the receptors in
the glomeruli and in the tubule segments (Figure 6B). This labeling
was specific, as established by preabsorption of the three
antibodies with their respective antigens (Figure 6B). We
performed dual immunofluorescence using the three antibodies
and a specific podocyte marker antibody against the Wilms’ tumor
1 (WT1) protein to study the expression of the receptors in the
podocytes of the human glomeruli. By immunolocalization, we
detected megalin, sortilin, and M6PR localization to podocytes as
demonstrated by colocalization with the podocyte cytoplasmic
marker WT1 protein (Figure 6C). The receptors were present
predominantly in podocyte cell bodies as seen on the merged high-
power views of the glomeruli (Figure 6C).
Discussion
In the present study, we have identified megalin, sortilin, and
M6PR in human podocytes as endocytic receptors required for the
delivery of recombinant a-Gal A to lysosomes. The M6PR
mediated pathway has been very well characterized as the major
route for the delivery of lysosomal enzymes; however, the
mechanism for delivery of a-Gal A to lysosomes in human
podocytes has been unclear until now. The heterogeneity of the
uptake system of a-Gal A offers new perspectives to improve ERT
for Fabry disease.
ERT given to Fabry patients has been shown to reduce GL-3
deposits in the podocytes [12,22,26], the principal affected cells
in the progress of nephropathy in Fabry disease [3,5,6,7]. The
glomerular filtration barrier allows macromolecules such as
albumin [41], transferrin, 80 kDa [42], and a pancreatic lipase,
110 kDa [43], to be filtered. Recently we have shown that there
is a limited but significant glomerular filtration of recombinant
a-Gal A in a-Gal A-deficient mice and Fabry patients [34].
These findings supported the hypothesis that ERT have an
effect on podocytes, which has now been enforced by
demonstration of uptake of recombinant a-Gal A by podocytes
i nak i d n e yf r o maF a b r yd i s e a s ep a t i e n t( F i g u r e1 A ) .T h e
uptake of a-Gal A in the glomerular endothelial and the
mesangial cells is currently under investigation and future
s t u d i e sw i l li nd e t a i lr e v e a lt h eu p t a k ei nt h e s ec e l l sa n dt h e
receptors involved.
We show here for the first time that megalin, sortilin, and
M6PR are expressed in the human glomerular podocytes. Using
laser capture microdissection to isolate human glomeruli, we show
that mRNA transcripts of megalin, sortilin, and M6PR are
expressed in human kidney cortex and in purified human
glomeruli. Immunoperoxidase staining identified a specific glo-
merular staining with a pattern highly suggestive of podocyte
labeling in the human kidney. Extraglomerular labeling was also
present in tubule segments. Dual immunofluorescence study
demonstrated that megalin, sortilin, and M6PR were all expressed
in the podocytes as verified by perfect colocalization with WT1
and labeling was confirmed to the cell body of the podocytes.
Furthermore, we also show that the expression of these receptor
proteins can be detected by immunofluorescence and Western blot
in human cultured podocytes.
Previous studies have described the presence of M6PR in the
proximal tubule and glomeruli [44,45]. Uptake of a-Gal A in
podocytes was reduced by more than 25% with the addition of
excess amounts of M6P. This was expected as the M6P residues on
the recombinant a-Gal A are targeting the signal for the high-
efficiency uptake by M6PR [32,33]. M6PR is primarily (90–95%)
localized in the intracellular compartments, particularly in the
trans-Golgi network (TGN) and endosomes, with 5–10% of the
receptor present on the cell surface [46]. The primary function of
M6PR is to sort and transport M6P-bearing glycoproteins from
TGN to endosomes/lysosomes [46]. In addition, M6PR can bind
extracellular ligands and mediate endocytosis [47]. A small
proportion of M6PR was localized on the cell surface in podocytes,
and most of the M6PR was observed in intracellular compart-
ments.
Figure 3. Uptake of
125I-labeled a-Gal A by human podocytes.
(A) Human podocytes were incubated with
125I-a-Gal A for different
times. (B) Podocytes incubated with
125I-a-Gal A for 12 h in the
presence or absence of RAP, sortilin propeptide, M6P, and with all three
ligands combined at 37uC. Uptake was assayed as described in the
method section of the paper. Values are means of triplicate experiments
with standard deviations (SD). The addition of sortilin propeptide shows
no significant inhibition, however the addition of M6P, RAP or a
combination of all three inhibitors show significant reductions
(* indicate P,0.001) in the a-Gal A uptake after 12 h.
doi:10.1371/journal.pone.0025065.g003
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dent mechanisms exist for the uptake of a-Gal A. We expressed
full-length sortilin in sortilin negative HEK293 cells. These
transfected cells accumulated a-Gal A in intracellular compart-
ments, and the uptake was inhibited with NT, a high affinity
ligand for sortilin. These results demonstrated that sortilin is a
multifunctional receptor that binds recombinant a-Gal A and,
when expressed on the surface, mediates endocytosis. Sortilin is a
multifunctional receptor belonging to the Vps10p-domain family
receptors [38,48] and strongly homologous to that of the M6PR
[48]. Sortilin is like the M6PR mainly located in the Golgi
compartment and vesicles [38,48], but is also expressed on the cell
surface. Sortilin has been shown to co-localize with the M6PR,
both intracellularly and on the plasma membrane [49]. Thus, like
the M6PR, sortilin has the potential of functioning both as a
sorting receptor in the Golgi compartment and as a clearance
receptor on the cell surface. Our studies demonstrated that sortilin
like M6PR is located on the cell surface and in intracellular
compartments in human podocytes. Uptake and degradation
studies of
125I-labeled a-Gal A in human podocytes demonstrate
that sortilin and M6PR participate in the endocytosis of a-Gal A.
Our results show that sortilin could be a new receptor for a-Gal A
endocytosis in podocytes.
Megalin, a multiligand endocytic receptor, binds many of the
same ligands as sortilin, and is expressed in the renal tubular
epithelium and in many other organs [50,51]. Our results showed
that megalin is present in human podocytes, and takes part in the
uptake of a-Gal A. Megalin has previously not been described in
human podocytes; however, it has been described and located in
glomerular podocytes of rats [52], and also recently in cultured
mouse podocytes [53]. The affinity of a-Gal A for binding to
megalin is less than for sortilin [34]. Previous studies have shown
that cubilin do not bind a-Gal A [34], and we did not find binding
of a-Gal A to LRP (data not shown). These findings are consistent
with our previous results showing that megalin is the receptor
responsible for the proximal tubular accumulation of a-Gal A
[34]. It has been shown that apolipoprotein B (apoB) and apoE
rich lipoproteins are taken up by a receptor-mediated pathway in
primary podocytes isolated from a human carcinoma kidney [54],
and recently albumin was shown to be endocytosed by human
podocytes in vitro and in vivo [55]. The uptake of these and other
ligands could very well be facilitated by megalin, which is a
receptor for apoB, apoE and albumin [50,56,57].
The contribution of each of the receptors in vivo is difficult to
estimate based on our studies. RAP is a ligand for both megalin
and sortilin and it binds to megalin with a higher affinity (8 nM)
than for sortilin (78 nM) [58,59]. Thus, the inhibition of
125I-
labeled a-Gal A uptake with RAP may be due to the inhibition of
both megalin and sortilin receptors.
The expression of megalin, sortilin, and M6PR in human
podocytes is of general interest in the understanding of the rapidly
progressing podocyte physiology. In addition, the expression of
Figure 4. Binding and uptake of a-Gal A by sortilin. (A) SPR analysis of a-Gal A binding to purified human sortilin and inhibition of binding by
NT. The lower binding curve was corrected for the binding of NT itself to sortilin. (B) Uptake of Alexa-Fluor 488-labeled a-Gal A by wild-type and full-
length sortilin transfected HEK293 cells in the presence or absence of M6P or M6P and NT for 60 min at 37uC. At the given time, cells were fixed, and
analyzed by confocal microscopy. Scale bar, 10 mm.
doi:10.1371/journal.pone.0025065.g004
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initially discovered in 1982 as a pathogenic antigen of Heymann
Nephritis in rats [60]. Our findings suggest that also in human,
megalin may act as a pathogenic antigen for membranous
glomerulonephritis. In the context of Fabry disease identification
of two novel receptors on the podocyte opens new pathways of
investigations to improve even further ERT.
In Fabry disease the effective targeting of recombinant a-Gal A
depends on the M6P residues recognized by M6PR [31,32,33].
The limiting factor to this system includes the extent to which the
recombinant enzyme is modified with M6P and the distribution
of M6PR in different tissues. New approaches rely on the uptake
mechanisms different from the M6P-based using protein-based
mechanisms. Recently, a non-carbohydrate targeting platform for
lysosomal proteins was evaluated [61]. The authors described
that a fusion protein of b-glucuronidase with IGF-II, a high-
affinity M6PR ligand, improved the targeting to podocytes in
Mucopolysacccharidosis VII, another lysosomal disorder, where
the podocyte is the most severely-affected kidney cell-type [62].
They also showed that a-Gal A modified with attachment of
either apoE or IGF-II peptides increased the half-life by ,20-fold
in animal models, and that the in vitro uptake of these modified
enzymes was not competed by M6P. Recent data have shown
that fusion proteins between lysosomal enzymes and RAP were
efficiently endocytosed by fibroblasts and other cell types from
patients with lysosomal storage disorders. The uptake exceeded
that of the phosphorylated enzyme and was presumably mediated
by megalin and other members of low-density lipoprotein
receptor (LDLR) family [63]. Since sortilin and megalin bind
RAP, a fusion protein between a-Gal A and RAP could be used
for a more efficient cellular delivery of a-Gal A using other
pathways than M6PR. However, this will also target the other
members of LDLR family, thus sortilin provides an alternative
pathway using a fusion protein between a-Gal A and sortilin
propeptide [36], and may deliver the therapeutic enzyme
specifically via a sortilin mediated pathway.
In conclusion, we have identified M6PR, sortilin, and megalin
as the receptors responsible for the lysosomal delivery of a-Gal A
in human podocytes. Sortilin and megalin provide two M6P
independent uptake systems for the delivery of the recombinant a-
Gal A to the lysosomes in podocytes in Fabry disease patients.
These findings are important steps in developing a rationale for
ERT in Fabry disease.
Materials and Methods
Antibodies and proteins
Recombinant a-Gal A (Fabrazyme) and affinity-purified rabbit
polyclonal anti-human a-Gal A were provided by Genzyme Corp.
(Framingham, MA, USA). Sheep anti-rat megalin has been
described earlier [64]. A specific polyclonal rabbit anti-human
megalin was a kind gift from Dr. S. Moestrup, Aarhus University,
Aarhus, DK. This antibody gave a specific band for megalin when
tested by Western blot on human kidney homogenate. Recombi-
nant receptor-associated protein (RAP) was provided by Novo
Nordisk A/S (Bagsværd, DK) and Dr. S. Moestrup, Aarhus
University, Aarhus, DK. Affinity purified rabbit polyclonal anti-
sortilin was generated against the ectodomain of human sortilin, as
previously described [36]. Polyclonal rabbit anti-sortilin (ab16640)
and sortilin peptide (ab16686) were purchased from Abcam.
Recombinant GST-sortilin propeptide were expressed in Esche-
richia coli and purified as previously described [36]. A specific
affinity purified rabbit polyclonal anti-IGF-II/M6PR was gener-
ated against the full-length bovine IGF-II/M6PR as previously
described [65]. Polyclonal rabbit anti-rat IGF-II/M6PR 3637 was
a kind gift from Dr. W. Kiess, Hospital for Children and
Adolescence, University of Leipzig, Leipzig, DE. Recombinant
human IGF-II receptor (2447-GR) was purchased from R & D
systems (Minneapolis, MN, USA). The mannose 6-phosphate
(M6P; M3655), neurotensin (NT; N6383), affinity purified rabbit
polyclonal anti-podocin (P0372) were purchased from Sigma
Aldrich (Saint Louis, MO, USA). Monoclonal mouse anti-nephrin
IgG1 was a kind gift from Dr. K. Tryggvason, Karolinska
Institute, Stockholm, SE. Monoclonal mouse anti-human Wilms’
tumor 1 (WT1; clone 6F-H2) protein and peroxidase-conjugated
secondary antibodies were purchased from DAKO A/S (Glostrup,
DK). Fluorescence-conjugated secondary antibodies were pur-
chased from Molecular Probes (Eugene, OR, USA). Controls for
unspecific binding were performed with nonspecific rabbit, mouse,
or sheep IgG from DAKO.
Figure 5. Megalin, sortilin, and M6PR are expressed in cultured
podocytes. (A) Immunofluorescent demonstration of megalin, sortilin,
and M6PR in cultured human podocytes and (B) specific podocyte-
markers podocin and nephrin. Cells were fixed, stained with the
appropriate antibodies and detected with Alexa-Fluor-conjugated
secondary antibodies. Controls were incubated with serum and
detected with same secondary antibodies (data not shown). Nuclei
(blue) were stained with DAPI. Scale bars, 5 mm. White arrows indicate
potential cell surface labeling of the different receptors in the human
podocytes.
doi:10.1371/journal.pone.0025065.g005
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The human podocyte cell line conditionally immortalized by
introducing temperature-sensitive SV40-T antigen by transfection
has previously been characterized in detail [35]. The podocyte cell
line (passages 12 to 25) was maintained in RPMI 1640 (R-8758)
medium supplemented with insulin, transferrin, selenite (ITS; I-
3146), 10% FBS (F7524) all from Sigma Aldrich, at 33uCi n5 %
CO2. Podocyte differentiation was induced under nonpermissive
conditions by thermo shifting the cells to 37uC for 14 days. HEK
293 cells were obtained from Invitrogen (Carlsbad, CA, USA) and
maintained in DMEM (LONZA, BE) supplemented with 10% FBS
(GIBCO, Paisley, UK), at 37uCi n5 %C O 2. The human cDNA
construct encoding full-length sortilin [66] was expressed using the
mammalian expression vector pcDNA3.1/zeo (Invitrogen, Gronin-
gen, NL). Cells were transfected with pcDNA3.1/zeo using
FUGENE 6 (Roche, CH), and a stably transfected clone was
selected in medium containing 150 mg/ml zeocin. All cell culture
media were supplemented with 100 U/ml penicillin, and 100 mg/
ml streptomycin (LONZA). The media was renewed every second
day, and cells were split at confluence approximately once a week
using a trypsin-EDTA solution (LONZA). Experiments were
carried out with confluent monolayers of cells cultured in 24-well
plates (Nagle Nunc International, Hereford, UK) with or without
cover slips for uptake studies, and in 75 cm
2 culture flasks (Corning
Figure 6. Expression of megalin, sortilin, and M6PR in human glomeruli. (A) Expression of megalin, M6PR, sortilin, podocin, nephrin, APN
mRNAs by RT-PCR (+). Negative controls (2) run without RT enzyme. The marker used was 100 bp ladder. (B) Immunoperoxidase labeling of paraffin
sections from a normal human kidney incubated with antibodies to megalin, M6PR, and sortilin show that the brush borders of proximal tubules (PT)
are heavily stained. The distal tubules (DT) are unstained for megalin, but stained for sortilin and M6PR. The glomeruli (G) show staining for megalin,
sortilin and M6PR. Preabsorption of the antibodies with the respective antigens show loss of immunoreactivity, demonstrating antibody specificity.
Tubular and podocyte staining was blocked by preincubation. Controls that included only the secondary antibody showed no labeling (data not
shown). Scale bar, 50 mm. (C) Dual immunofluorescence and confocal microscopy with monoclonal anti-WT1 antibody (red) and polyclonal antibodies
(green) against megalin, sortilin, and M6PR. The respective merge images are shown in both low and high magnifications. Megalin, sortilin, and M6PR
are localized in the glomerular podocytes and co-localizes with WT-1 as seen by the merged images indicated with white arrow-heads. High-power
views of a portion of a glomerulus show merged images of the receptors and WT1 demonstrating that megalin, sortilin, and M6PR localize primarily
to the podocyte cell bodies. Scale bar, 50 mm.
doi:10.1371/journal.pone.0025065.g006
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experiment. Podocytes were only used after they were differentiated
under non-permissive conditions for 14 days at 37uC.
Biopsy preparation
Renal biopsies were obtained from A) a kidney from a male
Fabry patient, 37 years of age, 2 h after enzyme replacement
infusion, 0.2 mg/kg body wt recombinant a-Gal A and B) an
untreated male Fabry patient, 38 years of age. The biopsies were
prepared for paraffin-embedding by routine methodology. Ethical
approval for the human studies was granted by the Copenhagen
Local Research Ethics Committee and informed consent was
obtained from the patient.
Immunofluorescence microscopy of cell cultures
Uptake of Alexa Fluor 488-labeled a-Gal A in cultured
human podocytes. Recombinant a-Gal A was labeled with
Alexa Fluor 488 according to the instructions of the manufacturer
(Molecular Probes). Podocytes, parental and full-length sortilin
HEK293 cells were incubated with Alexa Fluor 488-labeled a-Gal
Aa t3 7 uC at indicated times with or without inhibitors, and fixed
with 4% paraformaldehyde for 10 min at room temperature.
LysoTracker Red DND-99 (L-7528; Molecular Probes) was used
as described by the manufacturer. Cells were counterstained with
LysoTracker Red for 15 min before fixation.
Localization of proteins in podocytes. Immunofluore-
scence on human podocytes was performed as described
previously [35] at room temperature. In brief, cover slips were
fixed with 2% paraformaldehyde, 4% sucrose in PBS for 10 min
and permeabilized with 0.3% Triton X-100 (Sigma Aldrich) in
PBS for 10 min. Nonspecific binding sites were blocked with 4%
FBS+0.1% Tween 20 (Sigma Aldrich) in PBS for 60 min. Primary
and secondary antibodies were applied at the appropriate dilutions
according to standard techniques.
Cell surface localization of proteins in podocytes. For
surface labeling of proteins, cover slips were fixed with 2%
paraformaldehyde, 4% sucrose in phosphate-buffered saline and
incubated with primary antibodies over night at 4uC. After this,
they were incubated with Alexa Fluor conjugated antibodies for
1 h at room temperature, and nuclei-stained with DAPI
(Molecular Probes) according to the directions from manufacturer.
All cover slips were mounted on glass slides in DAKO
Fluorescent Medium. Staining was analyzed by confocal laser
scanning microscope (LSM510; Carl Zeiss, DE). Images were
acquired using the software from the manufacturer and processed
with Adobe Photoshop CS3 software. Controls for nonspecific
binding were performed with nonspecific serum and IgG fractions.
Protein extraction
Cell proteins were extracted by addition of modified RIPA
buffer (R-0278; Sigma Aldrich) containing 50 mmol/L Tris-HCL,
150 mmol/L NaCl, 1% Triton X-100, 1 mmol/L ethylenedi-
aminetetraacetic acid, 1 mmol/L phenylmethyl sulfonyl fluoride,
1 mg/mL aprotinin, 1 mg/mL leupeptin, 1 mg/mL pepstatin,
1 mmol/L Na vanadate; and complete protease inhibitor (Roche
Diagnostics, Mannheim, DE; 1 tablet per 50 ml of solution) at
4uC. The suspension was centrifuged at 140006g for 15 min at
4uC, and the supernatant containing cellular protein was collected.
Total protein was quantified using Pierce BCA Protein Assay kit
(Pierce, Rockford, IL, USA) according to the manufacturer.
Affinity purification of a-Gal A binding proteins
Purified recombinant a-Gal A covalently coupled using the
AminoLink Plus Immobilization Kit (Pierce) following the
guidelines from the manufacturer. Affinity purification was done
following the Pierce instructions. Briefly, differentiated podocytes
were lysed with RIPA buffer as described before. The cell lysate
was diluted in PBS binding buffer (pH 7.4) at a ratio of at least 1:4
and recirculated over the column three times at room tempera-
ture. The column was extensively washed in wash solution (1 M
NaCl, 0.05% NaN3) followed by elution of bound proteins with
0.2 M glycine?HCl buffer (pH 2.5). Fractions (300 ml) were
collected, subjected to SDS-PAGE, and stained by silver staining
using SilverSNAP Stain Kit II (Pierce). Additional gels were
blotted onto PVDF membranes for further protein identification
by Western blotting.
SDS-PAGE and Western blotting
Eluted a-Gal A binding protein fraction with the highest protein
content and podocyte lysates were loaded on the SDS-PAGE gels.
The samples were mixed with NuPAGE LDS sample buffer
(Invitrogen, Carlsbad, CA) with 2.5% SDS, and the proteins were
separated by SDS-PAGE and electrophoretically transferred to
PVDF membranes (Millipore Corporation; Bedford, MA, USA)
for Western blot. Blots were blocked with 5% milk in PBS-T
(80 mM Na2HPO4, 20 mM NaH2PO4, 100 mM NaCl, and 0.1%
Tween 20 [pH 7.5]) for 1 h and incubated overnight at 4uC with
primary antibody in PBS-T with 1% BSA. After washing in PBS-
T, the blots were incubated for 1 h with horseradish peroxidase-
conjugated secondary antibody (DAKO). After a final wash,
antibody binding was visualized using ECL system (Amersham
International, Bucks, UK).
Surface plasmon resonance analysis
For the surface plasmon resonance (SPR) analyses, BIAcore
sensor chips (type CM5; Biacore, Uppsala, SE) were activated with
a 1:1 mixture of 0.2 M N-ethyl-N9-(3-dimethylaminopropyl)
carbodiimide and 0.05 M N-hydroxysuccinimide in water accord-
ing to the manufacturer. Sortilin was immobilized as previously
described [36]. The SPR signal from immobilized sortilin
generated BIAcore resonance units (RU) that were equivalent to
66 fmol/mm
2. The flow cells were regenerated with 20 mlo f
1.5 M glycine-HCl (pH 3.0). The flow buffer was 10 mM HEPES,
150 mM NaCl, 1.5 mM CaCl2, and 1 mM EGTA (pH 7.4). The
binding data was analyzed using the BIAevaluation program. The
number of ligands bound per immobilized receptor was estimated
by dividing the ratio RU ligand/mass ligand with RU receptor/
mass receptor. The Kd for binding was estimated using a BIA
evaluation program.
125I-labeled a-Gal A uptake by podocytes
Lysosomal a-Gal A was iodinated with the use of the
chloramine-T method [67] to a specific activity of approximately
217,000 cpm/mg protein. Human podocytes were incubated with
10 nM
125I-a-Gal A in the presence or absence of 1 mM RAP,
10 mM M6P, 1 mM sortilin propeptide, and all three ligands at
37uC in 5% CO2/95% air for 4, 8, and 12 h. Incubation with
125I-a-Gal A was carried out in serum-free medium (RPMI1640)
containing 0.1% BSA (Sigma Aldrich), and stopped by aspiration
of the medium. Cells were washed in PBS and collected by
trypsinization with 150 ml of Trypsin-EDTA. The samples were
counted in a c-counter (Cobra 5003, Packard, Meriden, CT,
USA). Degradation was measured by precipitation of the medium
in 10% TCA and the TCA-soluble fraction, defined as the
degraded fraction. To correct for liberation per se of iodine from
125I-a-Gal A during the experiment, the medium in control wells
was incubated without cells. Degradation was calculated as the
TCA-soluble fraction in the incubation medium minus the TCA-
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125I-a-Gal A was measured by counting the cells after trypsiniza-
tion. Total uptake was defined as the sum of degraded and cell-
associated fraction divided by the total amount of tracer added in
each well. The medium from control wells contained a TCA-
soluble fraction of approximately 10%.
Tissue Preparation and LCM
Human kidneys were obtained from renal carcinoma patients.
Ethical approval for the human studies was granted by the Local
Research Ethics Committee and informed consent was obtained
from the patients. Immediately after surgical removal, carcinoma
free parts of the kidneys were excised, embedded in Tissue-Tek
OCT Compound, and immediately snap-frozen, placed on dry ice
and stored at 280uC until use. Tissues were cryosectioned into
10 mm thick sections at 220uC using a cryostat. Cryosections were
then attached to RNase-free glass slides (Arcturus, Mountain
View, CA, USA). The slides were processed with an RNase-free
technique. The slides were thawed at room temperature for 30 sec
and then dehydrated in 75% ethanol for 1 min, 95% ethanol for
1 min, and 100% ethanol for 1 min. Finally, sections were
incubated in xylene for 5 min and air dried for 5 min.
Immediately after dehydration LCM was performed using the
automated VERITAS
TM Microdissection Instrument (Arcturus).
The laser beams were adjusted to cut and capture the visualized
glomeruli. Dissection was performed at room temperature and was
limited to 30 min to prevent RNA degradation. CapSure HS
LCM caps (Arcturus) were used to capture the glomeruli, ensuring
precise capture and preventing contamination from the surround-
ing tissue while microdissecting. Furthermore, CapSure HS LCM
caps together with ExtracSure devices (Arcturus) enabled the
highly sensitive extraction of glomeruli. For RNA extraction, a
total of 200 glomeruli were captured.
RNA Isolation and RT-PCR
Total human glomerular- and cortex RNA were extracted using
the PicoPure RNA Isolation Kit (Arcturus) as described by the
manufacturer. DNase treatment was performed on PicoPure
column with a RNase-free DNase set (Qiagen, Hilden, DE). Total
RNA was estimated using a NanoDrop 2000 (Thermo Scientific,
Wilmington, DE, USA), showing that each sample yielded 3–
8 ng/ml.
Reverse transcription was performed for 60 minutes at 42uCi n
a volume of 20 ml using Sensiscript RT (Qiagen) and respective
buffer. This was performed in the presence of 0.5 mM
deoxyribonucleoside triphosphates (dATP, dTTP, dGTP, dCTP)
(Qiagen), 1 mM of a 16mer d(T) oligonucleotide primer (Perkin
Elmer, USA), 0.5 unit/ml RNase inhibitor (Perkin Elmer), 1 ml
Sensiscript RT and purified RNA (25 ng). A reaction without RT
enzyme was made in parallel with purified RNA to ascertain that
the amplification occurred on RNA and not DNA.
PCR was performed in a volume of 10 ml using a HotStarTaq
Master Mix Kit (Qiagen) following the protocol from manufac-
turer. This was performed with 5 ml HotStarTaq Master Mix,
2.5 ml cresol, 5 pmol of sense and antisense primers (Table 1) and
1 ml of the RT-product. The PCR program was as follows:
denaturation 15 min 94uC and 35 cycles of: 1 min 94uC, 30 sec
58uC, 1 min 72uC. After cycling the reaction ended with 10 min
at 72uC. After the PCR reaction the products were visualized by
running a 1.5% agarose gel stained with ethidium bromide




Renal sections were obtained from paraffin-embedded Fabry
disease kidneys or normal human kidneys (autopsy materials). For
light microscope immunohistochemistry, 2-mm tissue paraffin
sections were cut on a Leica RM 2165 microtome (Leica, Wetzlar,
Germany). Sections were dried at 60uC in an oven for 1 h, placed
in xylene overnight, rehydrated in graded alcohols, heated in TEG
buffer (Tris-EGTA buffer, pH 9) at approximately 100uCi na
microwave oven for 20 min, cooled at room temperature for
30 min, incubated for 30 min in 50 nM NH4Cl in 0.01 M PBS.
Sections were permeabilized with 0.05% saponin (1% BSA, 0.2%
gelatine, 0.05% saponin in 0.01 M PBS) and blocked for
endogenous peroxidase before incubation with the primary
antibody. Sections were incubated with a primary antibody in
0.01 M PBS, 0.1% BSA and 0.02 M NaN3, followed by
incubation with HRP-conjugated secondary antibody. For the
preabsorption experiments, primary polyclonal rabbit anti-mega-
lin, anti-sortilin and anti-M6PR antibodies were incubated with
affinity purified megalin, sortilin, and M6PR respectively for 2 h at
room temperature before incubating the preincubated antibody
and antigen mixture on the tissue-slide. Megalin was purified from
human cortical membranes on RAP affinity column, using the
AminoLink Plus Immobilization Kit and human cortical mem-
branes were obtained from human kidneys and prepared as
previously described [68]. Sortilin and M6PR were purchased
Table 1. Primers for RT-PCR.
Transcript GenBank accession # Primer pair Product size bp
Megalin NM_004525.2 59-AGCCTCTGGAGTTGGACAGA-39 (forward)
59-ACAGTGCGGTTAGACCCATC-39 (reverse)
189
M6PR NM_000876.2 59-AGTGGAAGGGGACAACTGTG-39 (forward)
59-ACATGAGGAGACCACCTTGG-39 (reverse)
184
Sortilin NM_002959.4 59-TCCTGGGTTGGAGATAGCAC-39 (forward)
59-TTCCTCCAGACACCTCTGCT-39 (reverse)
232
Podocin NM_014625.1 59-TGGGGAATCAAAGTGGAGAG-39 (forward)
59-GAATCTCAGCTGCCATCCTC-39 (reverse)
169
Nephrin NM_004646.1 59-GACCCAGCTTCCCATCACTA-39 (forward)
59-GCATTGGAGAGGAGCAGAAG-39 (reverse)
150
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counterstained with Meier’s haematoxylin stain and peroxidase
labeling was visualized by incubation with diaminobenzidine and
H2O2 for 10 min.
For dual immunofluorescence labeling mouse anti-WT1 and
rabbit anti-megalin (antiserum), anti-sortilin (immunopurified
polyclonal antibody to human sortilin), or anti-M6PR (immuno-
purified polyclonal antibody to bovine M6PR) antibodies were
applied followed by Alexa Fluor conjugated anti-mouse and anti-
rabbit IgG. All incubations with primary antibodies were done
overnight at 4uC and secondary incubations were done at room
temperature for 1 hour. Sections were subsequently examined in a
Leica DMR microscope equipped with a Leica DFC320 camera
or a Zeiss LSM510 Meta laser confocal microscope. Images were
transferred by a Leica TFC Twain 6.1.0 program and processed
using Adobe Photoshop 8.0. Negative controls were performed by
replacing the primary antibody with the normal serum of the




125I- a-Gal A uptake experiments are presented as
means 6 SD, and the t test was used to test for significant
differences. P values,0.05 were considered significant.
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